Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Treasury Shares (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Treasury Shares for 16 consecutive years, with $953713.0 as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 14.0% to $953713.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $953713.0 through Dec 2025, up 14.0% year-over-year, with the annual reading at $953713.0 for FY2025, 14.0% up from the prior year.
  • Treasury Shares for Q4 2025 was $953713.0 at Anika Therapeutics, roughly flat from $957338.0 in the prior quarter.
  • The five-year high for Treasury Shares was $957338.0 in Q2 2025, with the low at $53000.0 in Q2 2024.
  • Average Treasury Shares over 5 years is $605522.7, with a median of $720387.0 recorded in 2022.
  • The sharpest move saw Treasury Shares tumbled 93.56% in 2024, then surged 1706.3% in 2025.
  • Over 5 years, Treasury Shares stood at $158297.0 in 2021, then surged by 326.67% to $675405.0 in 2022, then tumbled by 72.16% to $188000.0 in 2023, then skyrocketed by 344.98% to $836562.0 in 2024, then increased by 14.0% to $953713.0 in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $953713.0, $957338.0, and $290792.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.